PacBio Cuts 28 Percent of Workforce, Citing Slower-than-Expected Adoption of Sequencers | GenomeWeb

By Monica Heger

Pacific Biosciences said today that it has had to cut approximately 130 employees, or 28 percent of its workforce, in response to "uncertainties associated with the economic environment" and a slower-than-projected adoption rate of its PacBio RS.

The company did not disclose specifics about the cuts, but operations and research and development were most affected. Hugh Martin will remain CEO and Eric Schadt will remain chief scientific officer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.